Should you buy Alnylam Pharmaceuticals (ALNY)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
ALNY currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Wide Moat Elite Growth Quality→Stable
- Confirmed Downtrend Blocks Entry↓Deteriorating
- Leverage Adds Downside Cushion Risk↑Improving
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Elite Growth Quality
Trip ifRevenue growth decelerates below 30% year-over-year for 2 consecutive quarters.
- P2Confirmed Downtrend Blocks Entry
Trip ifPrice closes above the 200-day moving average and on-balance volume turns positive for 20 or more consecutive sessions.
- P3Leverage Adds Downside Cushion Risk
Trip ifDebt-to-equity ratio falls below 1.5 within 4 consecutive quarters.
- P4Earnings Large Consistent Surprises
Trip ifEPS surprise falls below 0% in 2 of the next 3 reported quarters.
How the engine reached this verdict
TrendMatrix's engine output for Alnylam Pharmaceuticals, Inc. (ALNY) is SELL_IF_HOLDING with medium conviction, score 6.7/10 at $224.03. The C-path quality+growth combination cleared its gates — quality 8.2 and growth 10.0 — with 6.93 asymmetric R:R supporting the read.
The engine's exit framework anchors to a tactical sell band near $224.03, with structural invalidation at $209.00. The asymmetric R:R against a reversal hypothesis is 6.93 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
On the bull side: V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF); Sector modifier (Healthcare): +0.5; High-quality business. On the bear side: Leverage penalty (D/E 2.2): -1.5; Earnings in 6 days (event risk); Consecutive earnings misses (2). Active engine warnings: L3:NEWS_MOD=-2: STRONG_BUY_WAIT → SELL_IF_HOLDING, V9 Gate Failed: MOMENTUM:3.1<4.5, V9 Gate Failed: DEATH_CROSS:HARD_BLOCK.
The dominant failed gate is momentum at 3.1 vs threshold 4.5 (with co-failures: death cross, earnings proximity). SELL flips back toward HOLD if momentum recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is ASYMMETRY:6.9>=1.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ALNY — 10-dimension breakdown →
Bull case
- ▸V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸High-quality business
Bear case
- ▸Leverage penalty (D/E 2.2): -1.5
- ▸Earnings in 6 days (event risk)
- ▸Consecutive earnings misses (2)